Corrigendum to 'A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours' [Eur J Cancer 104 (November 2018) 1-8]

Affiliations

• ¹ Drug Development Department, Gustave Roussy Cancer Campus, 114 Rue Édouard-Vaillant, 94805 Villejuif Cedex, France. Electronic address: anas.gazzah@gustaveroussy.fr.
• ² Medical Oncology Division, START Madrid Centro Integral Oncológico Clara Campal, Calle de Oña, 10, 28050, Madrid, Spain.
• ³ Drug Development Department, Gustave Roussy Cancer Campus, 114 Rue Édouard-Vaillant, 94805 Villejuif Cedex, France.
• ⁴ Medical Oncology Division, START Madrid Centro Integral Oncológico Clara Campal, Calle de Oña, 10, 28050, Madrid, Spain; Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Calle Del Dr. Esquerdo, 46, 28007 Madrid, Spain.
• ⁵ Department of Head and Neck Cancer, Gustave Roussy Cancer Campus, 114 Rue Édouard-Vaillant, 94805 Villejuif Cedex, France.
• ⁶ Medical Oncology Phase I Unit, START Madrid Fundación Jiménez Díaz, Av. Reyes Católicos, 2, 28040 Madrid, Spain.
• ⁷ Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA.
• ⁸ Statistics, Syneos Health, 3201 Beechleaf Court, Raleigh, NC 27604, USA.
• ⁹ Medical Department, Boehringer Ingelheim, 12 Rue André Huet, 51721 Reims, France.